PBPK-PD model for predicting pharmacokinetics, tumor growth inhibition, and toxicity risks of topoisomerase inhibitor ADCs in mice and humans
All these results give a conclusion that the developed PBPK-PD model may be applied to predict the pharmacokinetics and therapeutical efficacy of T-DXd and SG as well as risk of ILD.
Authors
- Lan Tang (ORCID: https://orcid.org/0000-0002-2345-0886)
- Yongmei Tan (ORCID: https://orcid.org/0009-0005-7665-278X)
- Lan Sang
- Yanlin Zhao (ORCID: https://orcid.org/0000-0002-3028-3297)
- Zehua Wang (ORCID: https://orcid.org/0000-0001-6423-8219)
- Jinwei Zhu
- Kun Hao (ORCID: https://orcid.org/0000-0001-7537-9834)
- Sasa Zhang (ORCID: https://orcid.org/0000-0002-8478-1793)
Institutions
- China Pharmaceutical University (CN)
- Xuzhou Medical College (CN)
- Suizhou Central Hospital (CN)
- Xuzhou No.1 People's Hospital (CN)
- State Key Laboratory of Natural Medicine
Publication Details
- Journal
- European Journal of Pharmaceutical Sciences
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1016/j.ejps.2025.107234
- Citations
- 3
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- National Natural Science Foundation of China